Figure 6
From: Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation
Administration of PEG-HCCs suppresses T lymphocyte–mediated inflammation and ameliorates experimental autoimmune encephalomyelitis.
(a) An active DTH reaction was induced against ovalbumin in rats. Rats received either saline (vehicle) or PEG-HCCs (2 mg/kg body weight, subcutaneous) at time of immunization or challenge. Difference in ear thicknesses for each rat was measured 48 h after challenge. Healthy unimmunized rats are shown as a control (n = 5 rats per group). (b) Adoptive DTH induced in rats via adoptive transfer of antigen-activated GFP-transduced ovalbumin specific primary rat T cells. Treatment and ear measurements (left) identical to a. Detection of GFP-transduced ovalbumin-specific T cells in ears using FCM (right). Healthy rats that did not receive adoptive transfer or challenge are shown as a control (n = 10 rats in vehicle group; 9 rats in PEG-HCC-treated group). (c) Clinical scores of rats with acute active EAE, treated with saline (vehicle) or 2 mg/kg PEG-HCCs subcutaneously every 3 days, beginning at onset of disease signs (n = 6 rats per group). (d) Histological analysis of spinal cord gray matter collected from rats with EAE at the peak of disease (day 12 post-immunization) and stained with hematoxylin and eosin. Left, representative images. Arrows point to immune infiltrates. Scale bars, 100 μm. Right, quantification of degree of immune infiltration from eight random fields of view (n = 3 rats per group). Mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.
